中國天化工(00362.HK)盈喜:預期中期淨溢利同比增加約3463%至約2.75億港元
格隆匯2月15日丨中國天化工(00362.HK)公吿,集團預期於截至2022年12月31日止6個月相關期間錄得溢利淨額增加約2.68億港元,較截至2021年12月31日止6個月("同期")增加約3,463%,至約2.75億港元(同期溢利淨額:約700萬港元)。相關期間公司擁有人應占溢利淨額約為2.74億港元(同期公司擁有人應占溢利淨額:約600萬港元)。
相關期間溢利淨額增加主要由於牡丹江佳日熱電有限公司("佳日熱電")終止綜合入賬收益所致。佳日熱電正在申請自願清盤,當完成清盤程序後,公司可能就佳日熱電清盤後的所得收益進行應收賬回撥,並錄入為公司收益。
Follow us
Find us on
Facebook,
Twitter ,
Instagram, and
YouTube or frequent updates on all things investing.Have a financial topic you would like to discuss? Head over to the
uSMART Community to share your thoughts and insights about the market! Click the picture below to download and explore uSMART app!

Disclaimers
uSmart Securities Limited (“uSmart”) is based on its internal research and public third party information in preparation of this article. Although uSmart uses its best endeavours to ensure the content of this article is accurate, uSmart does not guarantee the accuracy, timeliness or completeness of the information of this article and is not responsible for any views/opinions/comments in this article. Opinions, forecasts and estimations reflect uSmart’s assessment as of the date of this article and are subject to change. uSmart has no obligation to notify you or anyone of any such changes. You must make independent analysis and judgment on any matters involved in this article. uSmart and any directors, officers, employees or agents of uSmart will not be liable for any loss or damage suffered by any person in reliance on any representation or omission in the content of this article. The content of the article is for reference only and does not constitute any offer, solicitation, recommendation, opinion or guarantee of any securities, virtual assets, financial products or instruments. Regulatory authorities may restrict the trading of virtual asset-related ETFs to only investors who meet specified requirements. Any calculations or images in the article are for illustrative purposes only.
Investment involves risks and the value and income from securities may rise or fall. Past performance is not indicative of future performance. Please carefully consider your personal risk tolerance, and consult independent professional advice if necessary.